GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Net Cash per Share

Theralase Technologies (TSXV:TLT) Net Cash per Share : C$-0.01 (As of Jun. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Theralase Technologies's Net Cash per Share for the quarter that ended in Jun. 2024 was C$-0.01.

The historical rank and industry rank for Theralase Technologies's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Theralase Technologies was 46.00. The lowest was 3.43. And the median was 10.67.

TSXV:TLT's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.185
* Ranked among companies with meaningful Price-to-Net-Cash only.

Theralase Technologies Net Cash per Share Historical Data

The historical data trend for Theralase Technologies's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Net Cash per Share Chart

Theralase Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.03 0.01 - -0.01

Theralase Technologies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Theralase Technologies's Net Cash per Share

For the Medical Devices subindustry, Theralase Technologies's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Price-to-Net-Cash falls into.



Theralase Technologies Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Theralase Technologies's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.044-1.371-0)/228.461
=-0.01

Theralase Technologies's Net Cash per Share for the quarter that ended in Jun. 2024 is calculated as

Net Cash per Share (Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.428-1.727-0)/239.295
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies  (TSXV:TLT) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Theralase Technologies Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Pinnacle Wealth Management, LLC

By GuruFocus Research GuruFocus Editor 07-29-2022

Top 5 4th Quarter Trades of Mechanics Bank Trust Department

By GuruFocus Research GuruFocus Editor 01-24-2023

Top 5 2nd Quarter Trades of SYNOVUS FINANCIAL CORP

By GuruFocus Research GuruFocus Editor 08-11-2022

Top 5 4th Quarter Trades of ONE PLUS ONE WEALTH MANAGEMENT, LLC

By GuruFocus Research GuruFocus Editor 01-19-2023

Top 5 3rd Quarter Trades of CADINHA & CO LLC

By GuruFocus Research GuruFocus Editor 10-22-2022

Top 5 2nd Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 07-26-2022

Top 5 3rd Quarter Trades of Barry Investment Advisors, LLC

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 3rd Quarter Trades of PINNACLE FINANCIAL PARTNERS INC

By GuruFocus Research GuruFocus Editor 10-31-2022

Top 5 2nd Quarter Trades of Louis Moore Bacon

By GuruFocus Research GuruFocus Editor 08-15-2022